U.S. payers are striking out at drug spending again, highlighting the cost to taxpayers. According to a commissioned report, 10 hot new "breakthrough" meds are expected to cost publicly funded healthcare plans more than $50 billion over the next decade.
Pharma companies that make payments to doctors--and the doctors who receive those payments--have repeatedly insisted there's no link between those payments and prescriptions. But data on Medicare's top script writers may have them answering for it all over again.
Pharma companies that make payments to doctors--and the doctors who receive them--repeatedly insist there's no link between those payments and prescribing habits. But data on Medicare's top script writers show the highest prescribers of particular meds collect big payments from the makers of those very drugs.
New numbers on federal drug spending may say something about prescribing patterns for Medicare patients. Perhaps too many scripts for branded Nexium, when a generic stomach acid reducer might do, for instance.
Is momentum growing behind the idea of Medicare taking a harder line on drug prices? Not in the pharma industry, that's for sure. But a new Inspector General's report adds some numbers to the argument, and as the New York Times reports, the government's precision medicine initiative might just push the issue.
The elimination of the Medicare Sustained Growth Rate formula that threatened large Medicare reimbursement cuts to doctors on an annual basis is the most significant entitlement reform achieved by the new Congress.
Industry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up?
The former owner, president and manager of Miami, FL-based Quick Solutions Medical Supplies, Angel Mirabal, has pleaded guilty to healthcare fraud charges, according to a statement from the U.S. Department of Justice.
Flush with success in negotiating discounts for hepatitis C drugs, payers are promising to strong-arm drugmakers in other treatment classes, too--cholesterol and cancer, for instance. They'll have more than one oncologist on their sides: A top doctor at the MD Anderson Cancer Center, fed up with cancer drug prices, plans a social media protest.
AdvaMed CEO Stephen Ubl said the med tech innovation ecosystem is "fraying" at a news conference unveiling the trade association's 2015 Innovation Agenda to fix the ills of the industry.